Daniel AuClair, PhD, Multiple Myeloma Research Foundation, Norwalk, CT, outlines the use of novel agents in the treatment of multiple myeloma. Dr AuClair highlights the use of immunotherapies and the FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy, idecabtagene vicleucel, for the treatment of patients with multiple myeloma and the potential approval of ciltacabtagene autoleucel in the future. This interview took place during the 3rd European Society of Hematology How to Diagnose and Treat Multiple Myeloma (ESH MM) 2021 congress.

свернуть